UBS AM
TEVA icon

UBS AM’s Teva Pharmaceuticals TEVA Stock Holding History

UBS AM’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130M Buy
3,832,465
+3,775,221
+6,595% +$126M 0.02% 459
2026
Q1 		$1.72M Buy
57,244
+51,590
+912% +$1.66M ﹤0.01% 2110
2025
Q4 		$176K Sell
5,654
-49,544
-90% -$1.22M ﹤0.01% 2471
2025
Q3 		$1.11M Sell
55,198
-4,616,537
-99% -$81.1M ﹤0.01% 1972
2025
Q2 		$78.3M Buy
4,671,735
+1,134,411
+32% +$18.3M 0.02% 586
2025
Q1 		$54.4M Buy
3,537,324
+196,261
+6% +$3.51M 0.01% 671
2024
Q4 		$73.6M Sell
3,341,063
-36,454
-1% -$663K 0.02% 580
2024
Q3 		$60.9M Buy
3,377,517
+2,376,668
+237% +$41.6M 0.02% 633
2024
Q2 		$16.3M Sell
1,000,849
-1,222,615
-55% -$18.8M ﹤0.01% 941
2024
Q1 		$31.4M Sell
2,223,464
-39,486
-2% -$498K 0.01% 688
2023
Q4 		$23.6M Sell
2,262,950
-27,401
-1% -$256K 0.01% 735
2023
Q3 		$23.4M Buy
2,290,351
+371,868
+19% +$3.46M 0.01% 734
2023
Q2 		$17M Hold
1,918,483
– – 0.01% 807
2023
Q1 		$17M Buy
1,918,483
+88,077
+5% +$871K 0.01% 807
2022
Q4 		$16.7M Buy
1,830,406
+153,181
+9% +$1.34M 0.01% 798
2022
Q3 		$13.5M Sell
1,677,225
-128,515
-7% -$1.14M 0.01% 866
2022
Q2 		$13.6M Buy
1,805,740
+5,980
+0.3% +$52.1K 0.01% 849
2022
Q1 		$16.9M Sell
1,799,760
-90,715
-5% -$757K 0.01% 887
2021
Q4 		$15.1M Sell
1,890,475
-23,365
-1% -$211K 0.01% 980
2021
Q3 		$18.6M Buy
1,913,840
+130,872
+7% +$1.23M 0.01% 888
2021
Q2 		$17.7M Sell
1,782,968
-88,857
-5% -$941K 0.01% 920
2021
Q1 		$21.6M Sell
1,871,825
-60,855
-3% -$698K 0.01% 845
2020
Q4 		$18.7M Sell
1,932,680
-17,610
-0.9% -$169K 0.01% 864
2020
Q3 		$17.6M Buy
1,950,290
+14,913
+0.8% +$158K 0.01% 810
2020
Q2 		$23.9M Sell
1,935,377
-57,980
-3% -$656K 0.01% 693
2020
Q1 		$17.9M Buy
1,993,357
+91,645
+5% +$939K 0.01% 701
2019
Q4 		$18.6M Buy
1,901,712
+177,129
+10% +$1.58M 0.01% 794
2019
Q3 		$11.9M Buy
1,724,583
+190,023
+12% +$1.46M 0.01% 903
2019
Q2 		$14.2M Sell
1,534,560
-302,680
-16% -$3.65M 0.01% 851
2019
Q1 		$28.8M Sell
1,837,240
-568,823
-24% -$10M 0.02% 658
2018
Q4 		$37.1M Buy
2,406,063
+984,975
+69% +$20.2M 0.03% 544
2018
Q3 		$30.6M Sell
1,421,088
-13,123
-0.9% -$305K 0.02% 640
2018
Q2 		$34.9M Buy
1,434,211
+51,428
+4% +$1.05M 0.03% 623
2018
Q1 		$23.6M Sell
1,382,783
-661
-0% -$12.9K 0.02% 728
2017
Q4 		$26.2M Buy
1,383,444
+13,930
+1% +$210K 0.02% 672
2017
Q3 		$24.1M Buy
1,369,514
+10,565
+0.8% +$238K 0.02% 695
2017
Q2 		$45.1M Sell
1,358,949
-6,213
-0.5% -$192K 0.04% 447
2017
Q1 		$43.8M Sell
1,365,162
-639,598
-32% -$21.8M 0.04% 446
2016
Q4 		$72.7M Buy
2,004,760
+1,205,253
+151% +$48.1M 0.08% 266
2016
Q3 		$36.8M Sell
799,507
-1,898,185
-70% -$99M 0.04% 470
2016
Q2 		$136M Sell
2,697,692
-317,981
-11% -$16.9M 0.15% 156
2016
Q1 		$161M Buy
3,015,673
+624,629
+26% +$36.6M 0.19% 120
2015
Q4 		$157M Buy
2,391,044
+583,167
+32% +$36M 0.18% 134
2015
Q3 		$102M Buy
1,807,877
+473,814
+36% +$30.7M 0.11% 206
2015
Q2 		$78.8M Sell
1,334,063
-216,121
-14% -$13.3M 0.08% 284
2015
Q1 		$96.6M Buy
1,550,184
+940,062
+154% +$54.7M 0.09% 245
2014
Q4 		$35.1M Sell
610,122
-13,864
-2% -$772K 0.03% 534
2014
Q3 		$33.5M Sell
623,986
-192,554
-24% -$10.2M 0.03% 540
2014
Q2 		$42.8M Sell
816,540
-37,079
-4% -$1.9M 0.04% 456
2014
Q1 		$45.1M Sell
853,619
-251,636
-23% -$11.6M 0.05% 406
2013
Q4 		$44.3M Sell
1,105,255
-979,907
-47% -$38.6M 0.05% 380
2013
Q3 		$78.8M Buy
2,085,162
+213,283
+11% +$8.32M 0.1% 234
2013
Q2 		$73.4M Buy
+1,871,879
New +$72.9M 0.09% 241

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

UBS AM's TEVA Position: Q2 2026 in Review

UBS AM increased its Teva Pharmaceuticals (TEVA) stake by 6,595% in Q2 2026, buying an estimated $126M and bringing the position to 3,832,465 shares worth $130M. The position accounts for 0.02% of the portfolio, ranked #459.

UBS AM first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $161M in Q1 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • UBS AM held 3,832,465 shares of Teva Pharmaceuticals worth $130M as of Q2 2026.
  • UBS AM bought 3,775,221 Teva Pharmaceuticals shares in Q2 2026, an estimated $126M.
  • Teva Pharmaceuticals made up 0.02% of UBS AM's portfolio in Q2 2026, its #459 holding.
  • UBS AM first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • UBS AM's Teva Pharmaceuticals position peaked at $161M in Q1 2016.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.